An Open-Label, Proof of Concept Study Designed to Evaluate the Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients with Newly Diagnosed, Moderate to Extensive Bullous Pemphigoid
Clinical Trial Grant
Administered By
Dermatology
Awarded By
Immune Pharmaceuticals
Start Date
July 1, 2016
End Date
June 20, 2020
Administered By
Dermatology
Awarded By
Immune Pharmaceuticals
Start Date
July 1, 2016
End Date
June 20, 2020